Table 4 Hepatic dysfunction occurrence rates based ons Rituximab administration
From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma
Use of rituximab | Patients with hepatic dysfunction (N = 40) (49.4%) | Patients without hepatic dysfunction (N = 41) (50.6%) | p-value |
|---|---|---|---|
Yes | 13 (32.5) | 14(34.1) | 0.88 |
No | 27(67.5) | 27(65.9) | Â |